Skip to content

Aerobic, Resistance, Inspiratory Training Outcomes in Heart Failure

Aerobic, Resistance, Inspiratory Training Outcomes in Heart Failure. The ARISTOS-HF Trial: a Prospective Randomized Multicenter Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03013270
Acronym
ARISTOS-HF
Enrollment
88
Registered
2017-01-06
Start date
2016-09-30
Completion date
2020-05-31
Last updated
2020-05-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure

Keywords

Rehabilitation, Exercise, Training

Brief summary

This study investigates the effects of aerobic, resistance, inspiratory training modalities outcomes in functional capacity and quality of life of heart failure (HF) patients, aiming for the 'optimum' (greek, αριστος=aristos) training program for HF patients.

Detailed description

Heart failure is a clinical syndrome characterized by symptoms of dyspnea, exercise intolerance and decreased quality of life. A weakness in both inspiratory and peripheral muscles is also reported. Aerobic training (AT) improves the functional status of HF patients (level of evidence IA). Additional benefits of inspiratory muscle training (IMT) and/or resistance training (RT) when combined with aerobic training (AT) in HF symptoms have also been found. Four exercise groups will be studied in order to identify the optimum exercise program I. Aerobic-Resistance-Inspiratory training (ARIS) group II. Aerobic Training-Resistance Training (AT/RT) group III. Aerobic training-Inspiratory Muscle Training (AT/IMT) group IV. Aerobic Training (AT) group

Interventions

OTHERAerobic-Resistance-Inspiratory

Patients will be submitted to a 12 week, 3 times/week, continuous aerobic (e.g. bike) training programme at an intensity of 60-80% max HR (or peakVO2) for 30 min combined with resistance training at an intensity of 50% of 1 Repetition Maximum (1RM) for quads training and upper limb exercises (elbow flex/shoulder flex/abd) using dumbbells (1-2 kg) (12-15 reps/3sets) for 10 min, combined also with inspiratory muscle training with a flow-resistive loading system at an intensity of 60% of maximal inspiratory pressure/sustained maximal inspiratory pressure (PImax/SPImax) for 20 min (Aerobic (30min) + Resistance (10min) + Inspiratory (20min) = 60 min)

Patients will be submitted to a 12 week, 3 times/week, continuous aerobic (e.g. bike) training programme at an intensity of 60-80% max HR (or peakVO2) for 30 min combined with resistance training at an intensity of 50% of 1RM for quads training, pectoralis m, serratus anterior m, and latissimus dorsi m and upper limb exercises (elbow flex/shoulder flex/abd) using dumbbells (1-2 kg) (12-15 reps/3sets). (Aerobic (30min) + Resistance (30min) = 60 min)

OTHERAerobic-Inspiratory

Patients will be submitted to a 12 week, 3 times/week, continuous aerobic (e.g. bike) training programme at an intensity of 60-80% max HR (or peakVO2) for 30 min combined with inspiratory muscle training with a flow-resistive loading system at an intensity of 60% of maximal inspiratory pressure/sustained maximal inspiratory pressure (PImax/SPImax) for 30min (Aerobic (30min) + Inspiratory (30min) = 60 min)

OTHERAerobic Training

Patients will be submitted to a 12 week, 3 times/week continuous aerobic (e.g. bike) training programme at an intensity of 60-80% max HR (or peakVO2) for 30 min combined with callisthenics progressing to treadmill or bike (at the same intensity) for 30 min (Aerobic training = 60 min)

Sponsors

Asklepieion Voulas General Hospital
CollaboratorOTHER_GOV
National Institute of Cardiology, Warsaw, Poland
CollaboratorOTHER
Onassis Cardiac Surgery Centre
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Chronic heart failure (from New York Heart Association (NYHA) functional class II to NYHA III) * Left ventricular ejection fraction below or equal to 35%

Exclusion criteria

* Uncontrolled arrhythmia * Pulmonary oedema or pulmonary congestion in the last 30 days * Cognitive, neurological or orthopaedic limitations * Respiratory infection during 30 days before the start of the study * Pulmonary limitations (e.g COPD)

Design outcomes

Primary

MeasureTime frameDescription
change in peak oxygen consumption (peakVO2, in ml/kg/min) using cardiopulmonary exercise testing (Medgraphics CPX/MAX, Medical Graphics Corp.,St. Paul, MN, USA, ZAN 600, ZAN Messgera¨te GmbH, Germany)Before and after 12 weeksevaluation of maximal exercise capacity
change in left ventricular dimension (mm) using resting 2-dimensional echocardiography (Ultrasound Vivid 7 or 6, General Electric Healthcare, Fairfield, CT, USA) with the Teichholz methodBefore and after 12 weeksevaluation of cardiac structure (LVEDD, LVESD in mm)

Secondary

MeasureTime frameDescription
change in left ventricular ejection fraction, echocardiography (Ultrasound Vivid 7 or 6, General Electric Healthcare, Fairfield, CT, USA) with the biplane Simpson' s methodBefore and after 12 weeksevaluation of LVEF%
change in walking distance using the 6-minute walking test (6MWT)Before and after 12 weeksevaluation of submaximal exercise capacity
change in quality of Life using the Minnesota Living with Heart Failure questionnaireBefore and after 12 weeksevaluation of life quality
Preference Program SurveyAfter 12 weeksQuestionnaire to evaluate exercise program preference (most enjoyed program) using a scale from 1 (=Very Little) to 5 (=Excellent)

Other

MeasureTime frameDescription
Change in skeletal muscle endurance will be evaluated using the quadriceps muscle endurance with the product: 50%1Repetition Maximum x max number of repsBefore and after 12 weeksevaluation of skeletal muscle endurance
Morbidity Records6 months and 12 months after completion of Exercise ProgramsEvaluate Morbidity
Change in dyspnoea using the Borg scale (0-10) at the end of exercise testingBefore and after 12 weeksevaluation of dyspnea
Change in maximal inspiratory pressure (PImax in cmH2O) using an electronic pressure manometer with computer software (TRAINAIR®, Project Electronics Ltd, London, UK).Before and after 12 weeksevaluation of inspiratory muscle strength
Change in inspiratory work capacity (sustained maximal inspiratory pressure (SPImax in cmH2O/s) using an electronic pressure manometer with computer software (TRAINAIR®, Project Electronics Ltd, London, UK).Before and after 12 weeksevaluation of an inspiratory muscle endurance index
Change in skeletal muscle strength will be evaluated using the quadriceps 1 repetition maximum (1RM)Before and after 12 weeksevaluation of skeletal muscle strength

Countries

Greece, Poland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 17, 2026